Streetbeat News

Analyst Ratings

HCA

Raymond James analyst John Ransom has maintained an 'Outperform' rating on HCA Healthcare (NYSE:HCA), but lowered the price target from $320 to $280.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:45 am

MANH

Rosenblatt analyst Blair Abernethy maintains a Neutral rating on Manhattan Associates (NASDAQ:MANH) and raises the price target from $196 to $200.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:44 am

DHR

Raymond James analyst Andrew Cooper has maintained an 'Outperform' rating on Danaher (NYSE:DHR) but lowered the price target from $250 to $240.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:43 am

CBU

Raymond James analyst Steve Moss has maintained an 'Outperform' rating on Community Bank System (NYSE:CBU) but lowered the price target from $60 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:40 am

UTZ

Jefferies analyst Rob Dickerson has initiated coverage on Utz Brands (NYSE:UTZ) with a Buy rating and a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:38 am

TRML

Piper Sandler analyst Yasmeen Rahimi has initiated coverage on Tourmaline Bio (NASDAQ:TRML) with an Overweight rating and a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:36 am

SN

Goldman Sachs analyst Brooke Roach has initiated coverage on SharkNinja (NYSE:SN) with a Buy rating and a price target of $52.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:35 am

FREY

TD Cowen analyst Gabe Daoud has downgraded FREYR Battery (NYSE:FREY) from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:33 am

EVGO

TD Cowen analyst Gabe Daoud has downgraded EVgo (NASDAQ:EVGO) from Outperform to Market Perform and lowered the price target from $6 to $4.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:31 am

MNRO

Monro (NASDAQ:MNRO) reported Q2 adjusted earnings of $0.41 per share, beating the analyst consensus estimate of $0.40 by 2.5%. However, the company's quarterly sales of $322.10 million missed the analyst consensus estimate of $331.01 million by 2.69%. This represents a 2.34% decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:31 am